TrialThe journal of prevention of Alzheimer's disease2025

Lower baseline amyloid beta burden is associated with greater percent of amyloid beta positron emission tomography reduction and better clinical outcomes in the aducanumab Phase 3 trials ENGAGE and EMERGE in early Alzheimer's disease.

Jackson Burton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.